Updates are available Correction dated 2022-06-29
Click to view Correction: https://doi.org/10.1038/s41588-022-01142-8
-
Authors
Turner, Adam W.
Hu, Shengen Shawn https://orcid.org/0000-0002-9691-7344
Mosquera, Jose Verdezoto https://orcid.org/0000-0002-2816-2250
Ma, Wei Feng
Hodonsky, Chani J. https://orcid.org/0000-0001-8566-5877
Wong, Doris
Auguste, Gaëlle https://orcid.org/0000-0003-4900-6959
Song, Yipei
Sol-Church, Katia
Farber, Emily
Kundu, Soumya
Kundaje, Anshul https://orcid.org/0000-0003-3084-2287
Lopez, Nicolas G.
Ma, Lijiang
Ghosh, Saikat Kumar B.
Onengut-Gumuscu, Suna https://orcid.org/0000-0002-6563-8334
Ashley, Euan A. https://orcid.org/0000-0001-9418-9577
Quertermous, Thomas https://orcid.org/0000-0002-7645-9067
Finn, Aloke V.
Leeper, Nicholas J. https://orcid.org/0000-0002-0905-2806
Kovacic, Jason C.
Björkegren, Johan L. M. https://orcid.org/0000-0003-1945-7425
Zang, Chongzhi https://orcid.org/0000-0003-4812-3627
Miller, Clint L. https://orcid.org/0000-0003-4276-3607
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (R01HL148239, R00HL125912, R01HL134817, R01HL125863, R01HL123370, R01HL130423, R01HL125863, R35GM133712)
Fondation Leducq (18CVD02)
American Heart Association (20POST35120545)
- License Information
-
More Information
Article History
Received: 4 June 2021
Accepted: 31 March 2022
First Online: 19 May 2022
Change Date: 29 June 2022
Change Type: Update
Change Details: In the version of this article initially published, the Reporting Summary linked to this article was incorrect and has now been replaced.
Change Date: 29 June 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41588-022-01142-8
Competing interests
: J.L.M.B. is a shareholder in Clinical Gene Network AB who have a vested interest in STARNET. A.V.F. at CVPath also acknowledges receiving financial support from the following entities: 4C Medical, 4Tech, Abbott Vascular, Ablative Solutions, Absorption Systems, Advanced NanoTherapies, Aerwave Medical, Alivas, Amgen, Asahi Medical, Aurios Medical, Avantec Vascular, BD, Biosensors, Biotronik, Biotyx Medical, Bolt Medical, Boston Scientific, Canon, Cardiac Implants, Cardiawave, CardioMech, Cardionomic, Celonova, Cerus, EndoVascular, Chansu Vascular Technologies, Children’s National, Concept Medical, Cook Medical, Cooper Health, Cormaze, CRL, Croivalve, CSI, Dexcom, Edwards Lifesciences, Elucid Bioimaging, eLum Technologies, Emboline, Endotronix, Envision, Filterlex, Imperative Care, Innovalve, Innovative, Cardiovascular Solutions, Intact Vascular, Interface Biolgics, Intershunt Technologies, Invatin, Lahav, Limflow, L&J Bio, Lutonix, Lyra Therapeutics, Mayo Clinic, Maywell, MDS, MedAlliance, Medanex, Medtronic, Mercator, Microport, Microvention, Neovasc, Nephronyx, Nova Vascular, Nyra Medical, Occultech, Olympus, Ohio Health, OrbusNeich, Ossio, Phenox, Pi-Cardia, Polares Medical, Polyvascular, Profusa, ProKidney, LLC, Protembis, Pulse Biosciences, Qool Therapeutics, Recombinetics, Recor Medical, Regencor, Renata Medical, Restore Medical, Ripple Therapeutics, Rush University, Sanofi, Shockwave, SMT, SoundPipe, Spartan Micro, Spectrawave, Surmodics, Terumo Corporation, The Jacobs Institute, Transmural Systems, Transverse Medical, TruLeaf, UCSF, UPMC, Vascudyne, Vesper, Vetex Medical, Whiteswell, WL Gore, Xeltis. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. The other authors declare no competing interests.
